4.7 Article

Contemporary Management of Severe Symptomatic Aortic Stenosis

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 78, Issue 22, Pages 2131-2143

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2021.09.864

Keywords

aortic stenosis; decision making; guidelines; surgical aortic valve replacement; transcatheter aortic valve replacement

Funding

  1. Abbott Vascular Inc
  2. Amgen Cardiovascular
  3. AstraZeneca
  4. Bayer AG
  5. Boehringer Ingelheim
  6. Boston Scientific
  7. Bristol Myers Squibb-Pfizer Alliance
  8. Daiichi-Sankyo Europe GmbH
  9. Alliance Daiichi-Sankyo Europe GmbH
  10. Eli Lilly and Company
  11. Edwards
  12. Gedeon Richter Plc
  13. ResMed
  14. Sanofi
  15. Servier
  16. Vifor
  17. Abbott
  18. Edwards Lifesciences
  19. Medtronic
  20. Biotronik
  21. GE Healthcare
  22. Bayer

Ask authors/readers for more resources

Despite a Class I recommendation for intervention, one in five patients with severe symptomatic AS chose not to intervene, a decision particularly associated with older age and combined comorbidities. Transcatheter intervention was extensively used in octogenarians.
BACKGROUND There were gaps between guidelines and practice when surgery was the only treatment for aortic stenosis (AS). OBJECTIVES This study analyzed the decision to intervene in patients with severe AS in the EORP VHD (EURObservational Research Programme Valvular Heart Disease) II survey. METHODS Among 2,152 patients with severe AS, 1,271 patients with high-gradient AS who were symptomatic fulfilled a Class I recommendation for intervention according to the 2012 European Society of Cardiology guidelines; the primary end point was the decision for intervention. RESULTS A decision not to intervene was taken in 262 patients (20.6%). In multivariate analysis, the decision not to intervene was associated with older age (odds ratio [OR]: 1.34 per 10-year increase; 95% CI: 1.11 to 1.61; P = 0.002), New York Heart Association functional classes I and II versus III (OR: 1.63; 95% CI: 1.16 to 2.30; P = 0.005), higher age adjusted Charlson comorbidity index (OR: 1.09 per 1-point increase; 95% CI: 1.01 to 1.17; P = 0.03), and a lower transaortic mean gradient (OR: 0.81 per 10-mm Hg decrease; 95% CI: 0.71 to 0.92; P < 0.001). During the study period, 346 patients (40.2%, median age 84 years, median EuroSCORE II [European System for Cardiac Operative Risk Evaluation II] 3.1%) underwent transcatheter intervention and 515 (59.8%, median age 69 years, median EuroSCORE II 1.5%) underwent surgery. A decision not to intervene versus intervention was associated with lower 6-month survival (87.4%; 95% CI: 82.0 to 91.3 vs 94.6%; 95% CI: 92.8 to 95.9; P < 0.001). CONCLUSIONS A decision not to intervene was taken in 1 in 5 patients with severe symptomatic AS despite a Class I recommendation for intervention and the decision was particularly associated with older age and combined comorbidities. Transcatheter intervention was extensively used in octogenarians. (J Am Coll Cardiol 2021;78:2131-2143) (c) 2021 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available